Isoray Announces the Appointment of Lisa Lauer As Vice President Business Development
February 16 2021 - 8:13AM
Isoray, Inc. (NYSE American: ISR), a medical technology company and
seed brachytherapy innovator, today announced that Lisa Lauer has
been appointed Vice President, Business Development.
CEO Lori Woods says Lauer’s appointment marks
another important step forward for the Company, “Lisa Lauer brings
deep industry experience and market knowledge to the Company.
Lisa's particular expertise in technologies used alone or in
combination with immunotherapy for the treatment of cancer make her
a perfect fit for Isoray. We believe Lisa will be an important
addition to our team as we continue to pursue our strategic plan
for growth opportunities in our core prostate business as well as
in the treatment of other cancers.”
Lisa Lauer brings more than 27 years of valuable
expertise across a broad range of therapeutic markets and a proven
track record in commercial execution, market access, reimbursement,
and strategic portfolio development and management.
Lauer joins Isoray following eleven years with
Olympus Corporation, a renowned precision technology leader
creating innovative opto-digital solutions in healthcare, life
science and consumer electronics products, where she has held a
number of leadership positions. Most recently, Lauer served as
Executive Director of Global Strategic Marketing within the
Therapeutic Solutions Division at Olympus. In that capacity, she
had direct responsibility over a broad endoscopic capital and
device portfolio focused on the diagnosis and treatment of
malignant and benign lung disease. Lauer was the recipient of the
Olympus Global CEO Award for leadership in 2019 for the commercial
launch of a novel endobronchial valve approved for treating both
acute and chronic lung conditions.
Lauer’s experience also includes more than ten
years with Johnson & Johnson where she earned numerous national
and regional awards in commercial healthcare sales that led to her
promotion into product marketing. Lauer distinguished herself early
in her tenure at the company when she became one of four people
selected to participate in Johnson & Johnson’s first Leadership
Development Program. While with Johnson & Johnson, Lauer worked
across the pharma, biotechnology, and device sectors for
immunology, anti-infectives, women’s health and analgesics
franchises.
Lauer returns to Isoray following her previous tenure from 2005
to 2009 as Director of Marketing during which time she developed
and implemented both upstream product and downstream commercial
strategies for the prostate market. In that role, she was also
instrumental in establishing a sales training program, initial
clinical strategy and advisory boards, and in developing Cesium-131
product branding.
Lauer’s appointment becomes effective today.
About Isoray Isoray, Inc., through its
subsidiary, Isoray Medical, Inc., is the sole producer of Cesium
Blu brachytherapy seeds, which are expanding brachytherapy
treatment options throughout the body. Learn more about this
innovative Richland, Washington company and explore the many
benefits and uses of Cesium Blu by visiting www.isoray.com.
Join us on LinkedIn and Facebook and follow us
on Twitter.
Safe Harbor Statement. Statements in this news
release about Isoray's future expectations, including whether the
hiring of Ms. Lauer will result in the successful identification
and consummation of growth opportunities in the Company’s core
prostate business as well as in the treatment of other cancers and
all other statements in this release, other than historical facts,
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 ("PSLRA"). This statement
is included for the express purpose of availing Isoray of the
protections of the safe harbor provisions of the PSLRA. It is
important to note that actual results and ultimate corporate
actions could differ materially from those in such forward-looking
statements based on such factors as whether the anticipated growth
opportunities will be identified and achieved. Unless required to
do so by law, we undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact
Media and Public Relations: Sharon Schultz (302) 539-3747
Investor Relations: Mark Levin (501) 255-1910
IsoRay (AMEX:ISR)
Historical Stock Chart
From Mar 2024 to Apr 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Apr 2023 to Apr 2024